Navigation Links
zPREDICTA Announces Revolutionary Cancer Drug Testing Platform

zPREDICTA™ today announces the immediate availability of its Reconstructed Bone Marrow (r-Bone™) platform, providing a radical shift in drug testing approach since the 1950s. r-Bone mimics how cells behave in the human body allowing cancer treatments to be tested under the same conditions as would be encountered in a patient. r-Bone helps identify drug candidates for blood cancers, which will ultimately work in patients, and thus, eliminates the guesswork from drug development. r-Bone is already being used in closed pilot programs by customers from 8 major pharmaceutical companies and leading universities, conducting thousands of tests on new anti-cancer drugs.

Methodologies used today to determine which drug candidates will advance to human trials comprise of plastic petri dishes and animals. These models show little predictive value when it comes to identifying the drugs that will demonstrate clinical benefit with over 90% of anticancer drugs failing human trials because they do not work in patients. The r-Bone platform reconstructs human biology where drugs can be tested directly against patients cells, a capability currently lacking in pharmaceutical industry.

"We would like a system that mimics the physiological bone marrow environment so we can work with patient AML bone marrow cells directly," said Hongmin Chen, Principal Scientist at Merck & Co., Inc. who has been working with zPredicta r-Bone kits.

r-Bone is the first product in zPREDICTA’s pipeline covering both blood cancers and solid tumors suitable for use with any drug class, including new immuno-oncology interventions, testing which presents a unique set of challenges not addressed by the available systems. Each product developed by zPREDICTA recreates a specific organ and incorporates specific conditions that arise due to disease. zPREDICTA’s technology provides a comprehensive platform that mimics human biology, which simple enough to be is easily incorporated into the existing drug development workflow. zPREDICTA performs thorough evaluation of each of its product through multiple peer-reviewed studies that validate its technology and demonstrate clinical relevance.

“By more accurately recreating the environment found inside the human body, zPREDICTA’s technology promises to dramatically reduce the time and money required to develop new anti-cancer drugs,” said Paul Buchheit, managing partner at Y Combinator and creator of GMail. “When we decide to invest in a company we look for breakthrough technology and a team that will be able to execute the vision, zPREDICTA has both.”


zPREDICTA, headquartered in San Jose, California is a biotechnology company founded in 2014 by 2 Ph.D. scientists, Julia Kirshner and Mukti Parikh on the principle that cures for human diseases require laboratory systems centered on human biology. zPREDICTA, backed by Y Combinator, the premier Bay Area accelerator, is a pioneer in organ-specific and disease-specific platforms for cancer drug testing. zPREDICTA technology demonstrates high clinical relevance allowing our pharma partners to identify drugs that will be effective in patients, from the hundreds, and often thousands, of compounds in development. The mission of zPREDICTA is to eliminate the guesswork from drug development, and thus, reduce the time and cost of bringing life-saving therapies to market.

Read the full story at

Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved

Related biology technology :

1. DistinctBright, Probiotic Cleaner, Announces their Probiotic Cleaner is Safe for Pets
2. Annual Conference about Technology Solutions for People with Disabilities Announces Program
3. Probiotic Action Announces Probiotics Lead the Digestive Health Market
4. Verenium Announces Preliminary Financial Results For Fiscal 2012
5. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
6. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
7. EAG Announces New General Manager of Release-To-Production (RTP) Division
8. DuPont Tate & Lyle Bio Products Announces Novel Application for Zemea® Propanediol
9. Probiotic Action Announces China’s $5 Billion Dollar Investment in Probiotics
10. EAS Consulting Group, Experts in Quality Regulatory Services Related to FDA Issues, Announces Upcoming Dietary Supplement Seminars in Salt Lake City
11. 3D Biomatrix Announces Stipend to Present at Spring 2013 Conferences
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions ... over 5.5 million people each year. Especially those living in larger cities are affected ... based in one of the most pollution-affected countries globally - decided to take action. ...
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
(Date:10/9/2017)... Jupiter, FL (PRWEB) , ... October 09, 2017 , ... ... episode, scheduled to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on ... Agriculture industry is faced with the challenge of how to continue to feed a ...
Breaking Biology Technology:
(Date:4/19/2017)... , April 19, 2017 The ... vendor landscape is marked by the presence of several ... however held by five major players - 3M Cogent, ... companies accounted for nearly 61% of the global military ... companies in the global military biometrics market boast global ...
(Date:4/13/2017)... PUNE, India , April 13, 2017 According ... Identity Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication ... by MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 ... Annual Growth Rate (CAGR) of 17.3%. ... ...
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
Breaking Biology News(10 mins):